{"meta":{"query_hash":"817cea60e012","filters":{"venue":"Expert Opinion on Emerging Drugs"},"cohort_total":45,"direct_labels_cover":0,"predictions_cover":45,"exported":45,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/817cea60e012","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Emerging+Drugs"},"results":[{"id":"W1974479297","doi":"10.1517/14728214.2014.955014","title":"Emerging drugs for levodopa-induced dyskinesia","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Levodopa; Medicine; Dyskinesia; Intensive care medicine; Disease; Parkinson's disease; Internal medicine","score_opus":0.05619929424255898,"score_gpt":0.39023074936603563,"score_spread":0.33403145512347665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974479297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030220977,0.98814887,0.0005278806,0.00072033517,0.004502331,0.00281154,0.0000841827,0.00041285853,0.0027617787],"genre_scores_gemma":[0.00043948457,0.9897496,0.0010284152,0.0007852162,0.0030654718,0.0016710641,0.0014543018,0.00041459562,0.0013918173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951764,0.00021462118,0.001176137,0.0015615264,0.0008673757,0.0010039541],"domain_scores_gemma":[0.99691653,0.00030622998,0.0007131961,0.0012888886,0.00016562181,0.00060951564],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004919016,0.0013166004,0.0032047683,0.00077242416,0.000424058,0.000071941635,0.00042724796,0.0005406278,0.00024878813],"category_scores_gemma":[0.00014507418,0.0010690882,0.001817514,0.00048612762,0.000041180916,0.000118133255,0.00012213206,0.00049464445,0.000428752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010660263,0.00040452578,0.0000011981346,0.0053698616,0.0006561139,0.000020295825,0.00056296657,6.4020276e-7,0.000007129121,0.0010645306,0.012703032,0.9791031],"study_design_scores_gemma":[0.0025272097,0.00042579454,0.0000030883664,0.01960748,0.0003836988,0.00003216992,0.0001850518,0.00015237348,0.00004975252,0.000063549356,0.9756561,0.0009137296],"about_ca_topic_score_codex":0.00005060306,"about_ca_topic_score_gemma":5.1627e-7,"teacher_disagreement_score":0.97818935,"about_ca_system_score_codex":0.0005111348,"about_ca_system_score_gemma":0.00042992827,"threshold_uncertainty_score":0.9999585},"labels":[],"label_agreement":null},{"id":"W1985544005","doi":"10.1517/14728214.2013.811487","title":"Inflammation and the heart – prime time for new therapeutic approaches","year":2013,"lang":"en","type":"letter","venue":"Expert Opinion on Emerging Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Coronary artery disease; Inflammation; Disease; Intensive care medicine; Clinical trial; Atherosclerotic cardiovascular disease; Cardiology; Internal medicine","score_opus":0.037059422539979,"score_gpt":0.2852610698547764,"score_spread":0.24820164731479738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985544005","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017327158,0.018162861,0.000778452,0.97536117,0.00077043584,0.0035898245,0.0000039521533,0.00011739818,0.0010426186],"genre_scores_gemma":[0.0012408658,0.00572525,0.0021921813,0.90695584,0.05943813,0.002075645,0.001151481,0.00033244654,0.020888172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796385,0.00019691004,0.00036789247,0.00048178068,0.0006129267,0.00037662845],"domain_scores_gemma":[0.9986771,0.0002290485,0.00015490914,0.00077458046,0.00006456554,0.00009982387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067406043,0.0003484789,0.00070066936,0.00012637308,0.00020339926,0.00007086136,0.00012905532,0.00043255245,0.00008969975],"category_scores_gemma":[0.000064923996,0.00021447112,0.0004358703,0.00009030716,0.00010140773,0.00007494906,0.000040513736,0.0006966548,0.00009248178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014378915,0.000012562523,0.0000015595866,0.00018376116,0.0003126197,7.557344e-7,0.0018424938,0.0000019831498,0.00005802911,0.00026032276,0.83031505,0.16686709],"study_design_scores_gemma":[0.0030116164,0.0001357418,0.0000394522,0.00031826503,0.0000363905,0.000025975287,0.000094668605,0.0013276122,0.00031683492,0.00023258083,0.9942217,0.00023914776],"about_ca_topic_score_codex":0.00026464247,"about_ca_topic_score_gemma":1.7866343e-7,"teacher_disagreement_score":0.16662794,"about_ca_system_score_codex":0.00008042729,"about_ca_system_score_gemma":0.00018332913,"threshold_uncertainty_score":0.87458783},"labels":[],"label_agreement":null},{"id":"W1999827505","doi":"10.1517/14728214.11.2.275","title":"Emerging drugs for the treatment of chronic obstructive pulmonary disease","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; COPD; Roflumilast; Pulmonary disease; Intensive care medicine; Pharmacology; Immunology; Internal medicine","score_opus":0.039661724835240206,"score_gpt":0.3782209013057312,"score_spread":0.338559176470491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999827505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003152928,0.98791003,0.00008575726,0.0009837298,0.0023682204,0.0062846798,0.00069939945,0.00015213586,0.0014845271],"genre_scores_gemma":[0.00027252053,0.9860827,0.00011139218,0.00005584784,0.0044682277,0.0036976347,0.00208536,0.00034485725,0.0028814706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418914,0.00030223883,0.0014079461,0.0015636709,0.0013516784,0.0011853302],"domain_scores_gemma":[0.9952818,0.0011473466,0.000756476,0.0019377682,0.00029945222,0.0005771615],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0002944566,0.0013014507,0.002605492,0.00071183377,0.0005425804,0.00004486055,0.00065878156,0.00032412482,0.00033821323],"category_scores_gemma":[0.00009505522,0.00088486215,0.0026282105,0.00081211276,0.0004989944,0.00014497877,0.00015946897,0.00051576865,0.000062223975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004026823,0.001475257,0.000015013555,0.012416988,0.0008048004,0.00004679228,0.0007119027,0.000043559627,0.0000020713683,0.00052618864,0.0030977332,0.980457],"study_design_scores_gemma":[0.0016007542,0.0003919111,0.00021538702,0.009539046,0.00060661323,0.000022655173,0.00065263524,0.0016657488,0.000011903401,0.00008345099,0.98448485,0.00072505046],"about_ca_topic_score_codex":0.000250045,"about_ca_topic_score_gemma":0.0000018095889,"teacher_disagreement_score":0.98138714,"about_ca_system_score_codex":0.0038773727,"about_ca_system_score_gemma":0.0020127613,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W2001823700","doi":"10.1517/14728210903142147","title":"Emerging drugs for prostate cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Angiogenesis; Androgen receptor; Pharmacology; Matrix metalloproteinase inhibitor; Tyrosine kinase; Cancer; Cancer research; Matrix metalloproteinase; Internal medicine; Receptor","score_opus":0.0657725239338676,"score_gpt":0.44593343913200534,"score_spread":0.38016091519813777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001823700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004216014,0.9855648,0.000017759026,0.0046525784,0.002438707,0.004327643,0.00015746006,0.00026882245,0.0025679895],"genre_scores_gemma":[0.000007135148,0.97951037,0.00030175433,0.0007155634,0.0027122966,0.0033041371,0.0013984658,0.00024775203,0.011802552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956538,0.00013415894,0.0009507207,0.0012166213,0.0008904764,0.0011542217],"domain_scores_gemma":[0.99790484,0.0002161307,0.00041698813,0.0008063744,0.00023174885,0.00042389202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044583468,0.0009618743,0.002315166,0.0007156483,0.00040271223,0.000078454694,0.00035382117,0.0003925847,0.00028009343],"category_scores_gemma":[0.000064466134,0.0007014549,0.0011308029,0.0006689191,0.000101053796,0.00013054923,0.00009417763,0.00073386723,0.0001142413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024836403,0.00020335021,0.0000018489172,0.0059245666,0.00041651056,0.0000124751095,0.0024673794,0.000001765197,0.0000029839496,0.00010650675,0.05837652,0.93223774],"study_design_scores_gemma":[0.0023046813,0.0004805795,0.0000012374536,0.034614533,0.00013840885,0.000010826415,0.00036944906,0.000056073473,0.000051122996,0.00003288501,0.9612657,0.0006745157],"about_ca_topic_score_codex":0.00011936673,"about_ca_topic_score_gemma":0.0000012386176,"teacher_disagreement_score":0.9315632,"about_ca_system_score_codex":0.0009959801,"about_ca_system_score_gemma":0.0010772186,"threshold_uncertainty_score":0.99954367},"labels":[],"label_agreement":null},{"id":"W2006321561","doi":"10.1517/14728210903107751","title":"Emerging drugs for major depressive disorder","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Agomelatine; Antidepressant; Monoamine neurotransmitter; Medicine; Norepinephrine; Dopamine; Serotonin; Pharmacology; Duloxetine; Melatonin; Neuroscience; Psychiatry; Receptor; Internal medicine; Psychology; Anxiety","score_opus":0.03552954744009842,"score_gpt":0.38616203259610443,"score_spread":0.35063248515600604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006321561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000765746,0.98668027,0.0003531397,0.0020697396,0.0028415092,0.0039645582,0.00007883453,0.00056065485,0.003443658],"genre_scores_gemma":[0.000025737547,0.98720336,0.002110218,0.0007224405,0.0025077155,0.0017053888,0.0018137443,0.00039936232,0.0035120214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994516,0.00022848224,0.0013674065,0.0017237122,0.001090505,0.0010738713],"domain_scores_gemma":[0.9964045,0.00055055507,0.0008733035,0.001548247,0.0001673456,0.0004560393],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00033298056,0.0014582127,0.003149103,0.0008640555,0.00052441773,0.000079747544,0.00055087527,0.00073944795,0.00030371684],"category_scores_gemma":[0.0002344587,0.001129898,0.0017917413,0.00051987363,0.00008401122,0.00020201218,0.00017738182,0.0007938205,0.00025250876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015348294,0.0005651552,0.000004942858,0.0034944382,0.00046418578,0.00001747336,0.0010403375,0.000003701838,0.0000027534882,0.0002031377,0.044506393,0.949544],"study_design_scores_gemma":[0.0039919713,0.00045050393,0.0000075169837,0.03782178,0.0003995942,0.000041914624,0.00027260702,0.000057602858,0.000032631207,0.00005705036,0.9558733,0.0009935041],"about_ca_topic_score_codex":0.00005272775,"about_ca_topic_score_gemma":8.9176973e-7,"teacher_disagreement_score":0.9485505,"about_ca_system_score_codex":0.0004941072,"about_ca_system_score_gemma":0.00032725057,"threshold_uncertainty_score":0.9998168},"labels":[],"label_agreement":null},{"id":"W2009384447","doi":"10.1517/14728214.2014.915025","title":"Emerging drugs for neuropathic pain","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Medicine; Neuropathic pain; Gabapentin; Intensive care medicine; Pharmacology; Alternative medicine","score_opus":0.04484334409380448,"score_gpt":0.3797579390529872,"score_spread":0.33491459495918274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009384447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.430687e-7,0.98463637,0.0069237007,0.00094150845,0.0035482615,0.0022458239,0.000032370437,0.00035011262,0.0013210108],"genre_scores_gemma":[0.00002980765,0.9895555,0.0016777809,0.0023659873,0.0024701,0.0011921638,0.00084202894,0.00035592463,0.0015107323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950002,0.0011030199,0.0010933304,0.0012420543,0.0007099124,0.0008515147],"domain_scores_gemma":[0.99662256,0.0011807614,0.00059214246,0.0011071318,0.00011659219,0.0003807812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032198448,0.0010465364,0.0026732446,0.00057899795,0.00037585353,0.000053768104,0.00035848343,0.0004664202,0.00013507147],"category_scores_gemma":[0.00074878783,0.00083092926,0.0014328613,0.00038171295,0.000047650014,0.00007025881,0.000100832556,0.00061549136,0.00026009002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035984307,0.00021044779,6.488801e-7,0.006053334,0.0002693463,0.000013735715,0.00069738406,0.0000010051458,0.000002192893,0.0010937823,0.012914351,0.9787078],"study_design_scores_gemma":[0.0012256961,0.0005180831,2.79509e-7,0.026080253,0.0001622527,0.000021952768,0.00016727932,0.0008446219,0.000008851151,0.000084843065,0.9702209,0.0006649943],"about_ca_topic_score_codex":0.000027087683,"about_ca_topic_score_gemma":2.4117267e-7,"teacher_disagreement_score":0.9780428,"about_ca_system_score_codex":0.00028615788,"about_ca_system_score_gemma":0.000248427,"threshold_uncertainty_score":0.99941415},"labels":[],"label_agreement":null},{"id":"W2016233068","doi":"10.1517/14728214.2012.678833","title":"Emerging targets for the treatment of scleroderma","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Scleroderma (fungus); Disease; Personalized medicine; Immunology; Bioinformatics; Pathology","score_opus":0.10231439979693052,"score_gpt":0.39166777573168,"score_spread":0.28935337593474947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016233068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004760351,0.9921586,0.000056745634,0.0004946128,0.004350822,0.002374119,0.000058576574,0.000082049366,0.00041971038],"genre_scores_gemma":[0.00015563336,0.9949531,0.00009611156,0.00012334198,0.0026858167,0.0010412772,0.00030083454,0.0001299536,0.0005139058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754214,0.00012032296,0.0009502031,0.0004741969,0.00043697926,0.00047615057],"domain_scores_gemma":[0.99775094,0.00056180236,0.0005713256,0.0008099995,0.00009621692,0.00020974051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024926846,0.0005791681,0.001774191,0.00024319858,0.00023225165,0.00001515058,0.00020991541,0.00030662108,0.00018149518],"category_scores_gemma":[0.000044544333,0.00030445895,0.001530401,0.00025264456,0.00007359672,0.00004327632,0.00002736755,0.00014744957,0.000054464934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045630703,0.0005516029,0.0000032418152,0.0027373463,0.00089401123,5.682872e-7,0.002004914,0.0000028012932,0.0000041825824,0.000097775286,0.008573506,0.9850844],"study_design_scores_gemma":[0.0010645883,0.00030032996,0.000008405978,0.02869214,0.00061162567,0.000011884381,0.00056280073,0.000058772595,0.000031723903,0.0000014561624,0.9683729,0.00028336482],"about_ca_topic_score_codex":0.000046042383,"about_ca_topic_score_gemma":1.6492012e-7,"teacher_disagreement_score":0.98480105,"about_ca_system_score_codex":0.0002450326,"about_ca_system_score_gemma":0.00017284835,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W2018561236","doi":"10.1517/14728214.9.1.191","title":"Superbugs & Superdrugs: A Focus on Antibacterials – 6th Annual SMi Conference","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Medicine; Cephalosporin; Antibiotics; Microbiology; Biology","score_opus":0.030020277683418035,"score_gpt":0.32962382828922154,"score_spread":0.2996035506058035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018561236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401798,0.0003883006,0.0009278706,0.042271763,0.000926278,0.00054521894,0.00015005379,0.00060229795,0.014008374],"genre_scores_gemma":[0.99054486,0.000739951,0.00053252745,0.0055040126,0.0010547206,0.000043873475,0.00033218568,0.000059963044,0.0011879082],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974666,0.00010339441,0.00053548726,0.0006740901,0.0007046899,0.0005157232],"domain_scores_gemma":[0.9986432,0.000068723144,0.00011244255,0.00062948395,0.00019539989,0.00035073265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027481155,0.00039982982,0.0005986202,0.00040725723,0.00023104923,0.0000663645,0.00016967923,0.00016497739,0.0016887914],"category_scores_gemma":[0.00014119009,0.00034494497,0.0003242242,0.00038320597,0.00012160819,0.00020397482,0.000053893855,0.00030525782,0.0009633609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042867046,0.008769479,0.0012840385,0.0003067562,0.001184871,0.00030846713,0.11950125,0.0007473851,0.59023273,0.041213203,0.17422523,0.05793988],"study_design_scores_gemma":[0.014288429,0.001670076,0.0019845017,0.0069751833,0.000043761276,0.000111897265,0.008019709,0.00015572093,0.19713454,0.00092334824,0.7668992,0.0017936171],"about_ca_topic_score_codex":0.00033915922,"about_ca_topic_score_gemma":0.000011184257,"teacher_disagreement_score":0.592674,"about_ca_system_score_codex":0.00016467251,"about_ca_system_score_gemma":0.00016104273,"threshold_uncertainty_score":0.9999003},"labels":[],"label_agreement":null},{"id":"W2019078592","doi":"10.1517/14728210802568764","title":"Emerging tocolytics: challenges in designing and testing drugs to delay preterm delivery and prolong pregnancy","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Preterm Birth and Chorioamnionitis","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic; University of Alberta","funders":"","keywords":"Medicine; Preterm delivery; Pregnancy; Intensive care medicine; Obstetrics; Pharmacology; Gestation","score_opus":0.08815268921509375,"score_gpt":0.3536720905677467,"score_spread":0.26551940135265295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019078592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005205587,0.99347174,0.00002195119,0.000374854,0.00051999144,0.0032857738,0.000010071179,0.00018987499,0.0016052038],"genre_scores_gemma":[0.0009988794,0.9940791,0.0024996842,0.00021878218,0.0005980713,0.0013303905,0.000043478703,0.00016671474,0.00006490931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960831,0.00024509124,0.0010189048,0.0012955199,0.00052288297,0.00083449326],"domain_scores_gemma":[0.9979263,0.00054677855,0.00035770098,0.0005788896,0.00010398996,0.00048636043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003070247,0.00086641574,0.0018338797,0.0008622172,0.00028698935,0.000063988045,0.00023286266,0.0004243282,0.000011820549],"category_scores_gemma":[0.00033914283,0.00079931034,0.00020873865,0.00045250353,0.00009648165,0.00021690935,0.00027449967,0.00080326566,0.000013196091],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000444707,0.000054200147,0.00009092624,0.00499531,0.00007597441,0.000120736506,0.010710626,0.0000017349967,0.000003990906,0.000023435856,0.00019018856,0.9836884],"study_design_scores_gemma":[0.0014722686,0.00075320667,0.000107441854,0.1918049,0.00006004981,0.0007093343,0.0011668085,0.00029850687,0.000021237918,0.000015416936,0.8024154,0.0011754372],"about_ca_topic_score_codex":0.000049144055,"about_ca_topic_score_gemma":0.0000031432885,"teacher_disagreement_score":0.98251295,"about_ca_system_score_codex":0.00022575702,"about_ca_system_score_gemma":0.00026403714,"threshold_uncertainty_score":0.9994458},"labels":[],"label_agreement":null},{"id":"W2019398901","doi":"10.1517/14728214.11.2.217","title":"Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Reverse transcriptase; Pharmacology; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Dosing; Drug; Regimen; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Internal medicine; Biology; RNA","score_opus":0.03402692502663547,"score_gpt":0.3494930753719826,"score_spread":0.31546615034534714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019398901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008444631,0.99231386,0.00007591548,0.0014852314,0.0018895427,0.0036247906,0.00006974859,0.00008190764,0.00037455047],"genre_scores_gemma":[0.000063686195,0.9927502,0.00029265936,0.00004677149,0.00077051093,0.0016795319,0.0012998801,0.00010635602,0.002990399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972387,0.00011868957,0.0011589075,0.000640226,0.00040725915,0.00043623394],"domain_scores_gemma":[0.9986366,0.0002741959,0.0004027556,0.000513765,0.000069974165,0.00010270995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023712424,0.0007027134,0.0016323206,0.0006881059,0.0001633441,0.000013643326,0.00010791939,0.0002599727,0.000055627122],"category_scores_gemma":[0.000029735347,0.00044355687,0.0010602965,0.0005735517,0.000059264294,0.00008568658,0.000013439804,0.0001991975,0.000029285931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002118944,0.0013687784,0.00011347385,0.0032403737,0.0004124516,0.000011132275,0.0053608846,0.000011405138,7.348012e-7,0.000075833894,0.026077705,0.96311533],"study_design_scores_gemma":[0.003607144,0.0003707622,0.000016644182,0.02046376,0.00021186935,0.000007869842,0.00029303005,0.00008663865,0.000049686587,0.0000036748133,0.9745359,0.0003530291],"about_ca_topic_score_codex":0.00043248452,"about_ca_topic_score_gemma":0.000026259177,"teacher_disagreement_score":0.9627623,"about_ca_system_score_codex":0.0007773846,"about_ca_system_score_gemma":0.00023909318,"threshold_uncertainty_score":0.99980164},"labels":[],"label_agreement":null},{"id":"W2025784617","doi":"10.1517/14728214.10.1.67","title":"The drug-based pipeline against restenosis","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Restenosis; Medicine; Drug; Conventional PCI; Sirolimus; Paclitaxel; Percutaneous coronary intervention; Intensive care medicine; Stent; Internal medicine; Cardiology; Pharmacology; Myocardial infarction; Chemotherapy","score_opus":0.05339832418767139,"score_gpt":0.3957091822183103,"score_spread":0.34231085803063893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025784617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012782251,0.984957,0.00006672409,0.006464638,0.0026435032,0.00088640116,0.0000403571,0.00017319343,0.0047669094],"genre_scores_gemma":[0.000022123722,0.990033,0.00022531261,0.0016429309,0.0025280511,0.0003592895,0.000718064,0.00012906725,0.004342172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711543,0.00020857208,0.0010526715,0.0005760421,0.0005758324,0.000471454],"domain_scores_gemma":[0.9970603,0.0010730001,0.00038352812,0.001121057,0.00013981429,0.00022231694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042994917,0.0005756869,0.0011566503,0.00030506757,0.00042698733,0.00006778207,0.00037327816,0.00021862617,0.00025108454],"category_scores_gemma":[0.0003568935,0.00036892766,0.0012924696,0.00038712725,0.000103186445,0.000041710136,0.00009353918,0.0006370536,0.00046515546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002406236,0.00025690635,0.0000010234135,0.00070954015,0.00006591874,0.000010328976,0.000088927074,0.000009137542,4.5786358e-8,0.00015676323,0.18230441,0.81637293],"study_design_scores_gemma":[0.00061473704,0.000119022865,0.000002207199,0.030744199,0.00007967144,0.000010893841,0.00016047512,0.00033822283,0.0000016667273,0.000002771804,0.96756846,0.00035768363],"about_ca_topic_score_codex":0.00002720769,"about_ca_topic_score_gemma":0.0000058131113,"teacher_disagreement_score":0.81601524,"about_ca_system_score_codex":0.00031948878,"about_ca_system_score_gemma":0.00035501955,"threshold_uncertainty_score":0.99987626},"labels":[],"label_agreement":null},{"id":"W2026842455","doi":"10.1517/14728214.2012.667800","title":"Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome","year":2012,"lang":"en","type":"letter","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory Support and Mechanisms","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; ARDS; Intensive care medicine; Acute respiratory distress; Disease; Clinical trial; Psychological intervention; Lung; Internal medicine; Psychiatry","score_opus":0.02716428527604438,"score_gpt":0.33935478079536313,"score_spread":0.31219049551931877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026842455","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17783576,0.15670092,0.0018330344,0.6118145,0.029536197,0.013975468,0.0049466225,0.0013266823,0.0020308152],"genre_scores_gemma":[0.07772817,0.05905961,0.0052463757,0.7817708,0.0359187,0.00643436,0.011350835,0.0021879578,0.020303186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695003,0.00009873858,0.00076987006,0.00078754453,0.00062397076,0.0007698652],"domain_scores_gemma":[0.9981933,0.00011524796,0.00048429845,0.00085890654,0.00012534313,0.00022288757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021011435,0.0007899049,0.001351035,0.0005306356,0.0002200738,0.000032484597,0.00019912323,0.0006884611,0.0001913992],"category_scores_gemma":[0.0000100645875,0.0006332523,0.00050963624,0.00015901908,0.000132223,0.00017124516,0.00006399569,0.00037201808,0.00001030767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010405937,0.00045846705,0.00057529274,0.00078057917,0.0050643305,0.00031224964,0.010184701,3.133013e-7,0.010968853,0.00016332253,0.8894597,0.080991566],"study_design_scores_gemma":[0.002127167,0.0022536556,0.00013552287,0.00064229534,0.00031718673,0.0000560153,0.00036139,0.000021660639,0.006929796,0.000021097703,0.98655427,0.00057997234],"about_ca_topic_score_codex":0.000021062348,"about_ca_topic_score_gemma":1.8972361e-7,"teacher_disagreement_score":0.1699563,"about_ca_system_score_codex":0.00022233142,"about_ca_system_score_gemma":0.00012912715,"threshold_uncertainty_score":0.99961185},"labels":[],"label_agreement":null},{"id":"W2026959104","doi":"10.1517/14728214.2014.882316","title":"Emerging drugs for cystic fibrosis","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Cystic fibrosis; Medicine; Cystic fibrosis transmembrane conductance regulator; Disease; Regulator; Genetic enhancement; Bioinformatics; Pathology; Internal medicine; Gene; Genetics; Biology","score_opus":0.03955102766984114,"score_gpt":0.4120936363719128,"score_spread":0.3725426087020717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026959104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010541681,0.986512,0.0036816224,0.0010171065,0.0032532685,0.0031299447,0.00013149845,0.00039805545,0.0018754231],"genre_scores_gemma":[0.000015385995,0.9812484,0.008875643,0.00042167155,0.003793636,0.001969826,0.0013790712,0.00041229738,0.0018841078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99356025,0.00033816195,0.0015849699,0.0016076546,0.0014931863,0.0014157565],"domain_scores_gemma":[0.9944829,0.0023686264,0.0006722442,0.0015372359,0.00028156093,0.0006574418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010422837,0.0012056623,0.0036365194,0.0010516692,0.00045793512,0.00011858609,0.0007009203,0.0004915392,0.00039228535],"category_scores_gemma":[0.0017057151,0.0009914611,0.0017075015,0.00080889347,0.00019144117,0.00017124358,0.00025118442,0.0009221928,0.00053422846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001903337,0.00013992938,3.7551607e-7,0.019613719,0.00026215496,0.0000039506945,0.00066322426,0.00000683556,0.000017155457,0.0005659593,0.05781899,0.92071736],"study_design_scores_gemma":[0.001315677,0.0006415849,6.498478e-7,0.050840143,0.00012545341,0.000030549145,0.00025648216,0.0004835811,0.00002853819,0.00007722451,0.9453243,0.00087578385],"about_ca_topic_score_codex":0.000047511872,"about_ca_topic_score_gemma":6.631974e-7,"teacher_disagreement_score":0.9198416,"about_ca_system_score_codex":0.0006642382,"about_ca_system_score_gemma":0.00054146943,"threshold_uncertainty_score":0.9992536},"labels":[],"label_agreement":null},{"id":"W2035771416","doi":"10.1517/14728214.13.1.63","title":"Emerging drugs for spinal cord injury","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; University of Toronto; Toronto Western Hospital","funders":"","keywords":"Medicine; Neuroprotection; Clinical trial; Spinal cord injury; Neuroscience; Bioinformatics; Intensive care medicine; Pharmacology; Spinal cord; Pathology; Biology","score_opus":0.12311867835735468,"score_gpt":0.4933757197572663,"score_spread":0.3702570413999116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035771416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016792023,0.9859328,0.00019586709,0.0013329374,0.004476955,0.0036649103,0.00008579983,0.0004159338,0.0038780004],"genre_scores_gemma":[0.000024068715,0.9863427,0.0016622636,0.00090766075,0.005213404,0.0017169951,0.00072734343,0.00047439322,0.0029311432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928908,0.0002918338,0.0017201063,0.0017502415,0.0018171986,0.001529841],"domain_scores_gemma":[0.99620795,0.0003525866,0.0006737411,0.0016552648,0.0004331682,0.0006772669],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007086275,0.0013578036,0.0034171152,0.0016262472,0.00063758815,0.0000772011,0.0008878873,0.0006983881,0.0004578662],"category_scores_gemma":[0.00051888416,0.0011806209,0.0020287645,0.001269448,0.00024319334,0.00019556377,0.0003309351,0.0017061301,0.00068348227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034333246,0.00021673072,9.0018534e-7,0.005310735,0.00027868728,0.000023599925,0.00020084348,1.3294218e-7,0.000005921546,0.00030509813,0.11607336,0.87415063],"study_design_scores_gemma":[0.0010818571,0.007931536,0.0000017415572,0.029646901,0.00007603401,0.00017397974,0.00032561028,0.000047313573,0.000036309677,0.000018526476,0.9596197,0.0010405013],"about_ca_topic_score_codex":0.000074241594,"about_ca_topic_score_gemma":3.2045003e-7,"teacher_disagreement_score":0.8731102,"about_ca_system_score_codex":0.0009250759,"about_ca_system_score_gemma":0.0012160898,"threshold_uncertainty_score":0.99991727},"labels":[],"label_agreement":null},{"id":"W2035774269","doi":"10.1517/14728214.8.2.297","title":"Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Telithromycin; Ketolide; Streptococcus pneumoniae; Microbiology; Macrolide Antibiotics; Efflux; Erythromycin; Medicine; Antibiotics; Biology","score_opus":0.11605327297256299,"score_gpt":0.4387001288850574,"score_spread":0.3226468559124944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035774269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021776505,0.98555696,0.00011779423,0.00062129716,0.005621754,0.003712559,0.00013507792,0.00061622116,0.0034005425],"genre_scores_gemma":[0.00011176229,0.99145895,0.000085036314,0.0018596003,0.002694683,0.0023812896,0.00027802086,0.00040911837,0.00072153006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946277,0.00058767945,0.0015674685,0.0015426244,0.0006431871,0.0010313065],"domain_scores_gemma":[0.9964931,0.0004576674,0.0007365654,0.0015053834,0.00020029246,0.0006070073],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00057384674,0.0014034171,0.0026278903,0.0016258925,0.0012659855,0.00013121561,0.00024840626,0.0007031461,0.00011049461],"category_scores_gemma":[0.00018597637,0.0011159227,0.001721666,0.0008148754,0.000121476,0.00019561216,0.000043535038,0.0007420612,0.00014431766],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010203086,0.0018842443,0.000013428586,0.0026689542,0.0007562869,0.000042259417,0.00088582357,0.00004534359,0.00031661015,0.0010559973,0.0034569376,0.9887721],"study_design_scores_gemma":[0.0016070659,0.0037937795,0.000004300496,0.012959288,0.00028416567,0.0000712527,0.00026159902,0.0000209437,0.000115254334,0.000021105607,0.9798583,0.0010029948],"about_ca_topic_score_codex":0.000049397808,"about_ca_topic_score_gemma":0.000009378893,"teacher_disagreement_score":0.98776907,"about_ca_system_score_codex":0.0018565428,"about_ca_system_score_gemma":0.0009990447,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W2040792648","doi":"10.1517/14728214.13.1.81","title":"Emerging drugs for malignant glioma","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glioma; Temozolomide; Radiation therapy; Oncology; Glioblastoma; Chemotherapy; Targeted therapy; Internal medicine; Cancer; Cancer research","score_opus":0.05204084896289074,"score_gpt":0.3800900213728202,"score_spread":0.3280491724099295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040792648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028289469,0.98980093,0.000034647383,0.0013161963,0.003510384,0.0029224367,0.00009490084,0.00030569997,0.0019865304],"genre_scores_gemma":[0.00008007059,0.99147284,0.0008668776,0.00050069054,0.00226754,0.0026595576,0.0014066478,0.00033361014,0.00041217543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952446,0.0001768284,0.0013218967,0.0013929075,0.00087672414,0.000987034],"domain_scores_gemma":[0.99703866,0.0005281302,0.0006170585,0.0011966454,0.00016804897,0.00045148013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028898555,0.0012210269,0.0030183094,0.0010163997,0.0005484011,0.00005491448,0.00036071258,0.00049569824,0.00021538202],"category_scores_gemma":[0.00013446517,0.00092791975,0.0021425893,0.0007163215,0.00009422723,0.00009905404,0.00012663353,0.0004884373,0.00035154665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058285565,0.00071968,0.000002358276,0.0028792953,0.00068106514,0.00013113634,0.0015208607,0.0000015916933,0.000004566687,0.00075664517,0.08797969,0.90526485],"study_design_scores_gemma":[0.0022591145,0.00041022905,0.0000016142187,0.026415879,0.00018105298,0.00033659834,0.00034758114,0.00004191675,0.00013193185,0.000018156867,0.9690329,0.00082305836],"about_ca_topic_score_codex":0.0000808874,"about_ca_topic_score_gemma":4.824319e-7,"teacher_disagreement_score":0.9044418,"about_ca_system_score_codex":0.00053867674,"about_ca_system_score_gemma":0.00035601648,"threshold_uncertainty_score":0.9993171},"labels":[],"label_agreement":null},{"id":"W2067328075","doi":"10.1517/14728210903203790","title":"Antigen-specific therapies in multiple sclerosis","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Multiple sclerosis; Effector; Antigen; Immunology; Immune system; Neuroscience; Biology","score_opus":0.2141295040898592,"score_gpt":0.40577077165303077,"score_spread":0.19164126756317157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067328075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003333079,0.99432534,0.0000114160575,0.0011214501,0.0010034314,0.0018753051,0.000021967924,0.0002197161,0.0013880711],"genre_scores_gemma":[0.0003219916,0.996552,0.00052410655,0.0003192182,0.0013081973,0.00048627716,0.00018643876,0.00016343073,0.00013833916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951315,0.0004009489,0.0011621275,0.001179639,0.0011534396,0.0009723743],"domain_scores_gemma":[0.9977026,0.00048783454,0.000309155,0.001108638,0.00012338144,0.00026838706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006481285,0.0009224781,0.0028451409,0.0012300471,0.00028037548,0.0000745304,0.00047397066,0.0004113794,0.00022448017],"category_scores_gemma":[0.00029613602,0.00071400794,0.0008760651,0.001043771,0.00018885758,0.00011736703,0.00017640987,0.0011055934,0.0003608686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065224725,0.0003992855,0.000038686438,0.00094835367,0.00017517211,0.000009925239,0.0022072666,0.0000010893579,0.000027247625,0.00004126852,0.017280182,0.9788063],"study_design_scores_gemma":[0.001410492,0.00018459452,0.00092435774,0.050973404,0.0000045294064,0.000004830129,0.00047630002,0.000024644673,0.000015302969,0.0000031881657,0.945401,0.00057734473],"about_ca_topic_score_codex":0.000097962184,"about_ca_topic_score_gemma":0.0000052707815,"teacher_disagreement_score":0.9782289,"about_ca_system_score_codex":0.0005666886,"about_ca_system_score_gemma":0.0001910677,"threshold_uncertainty_score":0.9995311},"labels":[],"label_agreement":null},{"id":"W2068824007","doi":"10.1517/14728214.2013.801453","title":"Emerging anti-inflammatory drugs for atherosclerosis","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Atherosclerosis and Cardiovascular Diseases","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Medicine; Inflammation; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.03811104574974039,"score_gpt":0.32115478340998305,"score_spread":0.28304373766024266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068824007","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006903399,0.9898814,0.00017501578,0.00010369439,0.0064924927,0.002190694,0.00019839022,0.00041504778,0.00047421685],"genre_scores_gemma":[0.000105909894,0.9931885,0.00009473445,0.0002623669,0.000918231,0.002590816,0.0011805481,0.00034719313,0.0013117063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953683,0.0006207186,0.0012432392,0.0014216154,0.000229097,0.0011170104],"domain_scores_gemma":[0.99719363,0.00038739585,0.0007244698,0.0014187042,0.00014756121,0.00012820694],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006257816,0.001249846,0.0028327198,0.00039374808,0.0007655637,0.00010928854,0.00093495066,0.0010009306,0.0009077817],"category_scores_gemma":[0.00008696427,0.0010413385,0.0035882867,0.0002956029,0.00022944194,0.0001946751,0.00025169505,0.00063287345,0.0021204676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012511908,0.00016819805,0.0000031685279,0.0017131644,0.0015005514,2.7530578e-7,0.0010404288,0.0000035482294,0.00020123308,0.0004247043,0.051416893,0.9435153],"study_design_scores_gemma":[0.0010499207,0.000086473556,0.000009686112,0.009085018,0.00020726318,0.000005440567,0.00069653965,0.0000030025612,0.00017863915,0.000011603594,0.98751825,0.0011481683],"about_ca_topic_score_codex":0.000040963976,"about_ca_topic_score_gemma":2.1079393e-7,"teacher_disagreement_score":0.94236714,"about_ca_system_score_codex":0.00022132792,"about_ca_system_score_gemma":0.00021680485,"threshold_uncertainty_score":0.9992037},"labels":[],"label_agreement":null},{"id":"W2075748215","doi":"10.1517/14728214.2015.985204","title":"Emerging drugs for celiac disease","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Celiac Disease Research and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Internal medicine","score_opus":0.04708593854982716,"score_gpt":0.4214706061184548,"score_spread":0.37438466756862765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075748215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.9054014e-7,0.9844673,0.000722102,0.0033688878,0.0026505063,0.004107061,0.00012677853,0.0003366709,0.0042200945],"genre_scores_gemma":[0.000010370894,0.9839794,0.00030186874,0.0013538763,0.0038299002,0.0026699016,0.0024313047,0.0003113539,0.005112032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946065,0.00023854665,0.001095991,0.0014288345,0.0013741103,0.0012560356],"domain_scores_gemma":[0.9959533,0.00038402964,0.00041059402,0.0015573299,0.0001926589,0.0015020363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008226558,0.0010109372,0.002361227,0.00093020115,0.0003790944,0.00011031724,0.0005306276,0.00024039322,0.00046921798],"category_scores_gemma":[0.0004352492,0.00083796604,0.002114068,0.0005117301,0.000103907805,0.00011536641,0.0003153714,0.0005660882,0.0005813288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019001315,0.00027974678,5.53163e-7,0.02080384,0.0003490743,0.000014737821,0.00022569722,0.000002167719,2.7332715e-7,0.0014664379,0.19692959,0.7797379],"study_design_scores_gemma":[0.0014912502,0.00020828238,0.0000013836285,0.02642606,0.00026474916,0.0000025829972,0.00022000638,0.00028723746,0.0000015915177,0.000060602644,0.970247,0.0007893048],"about_ca_topic_score_codex":0.000029853267,"about_ca_topic_score_gemma":3.0140563e-7,"teacher_disagreement_score":0.77894855,"about_ca_system_score_codex":0.00047181462,"about_ca_system_score_gemma":0.00064624584,"threshold_uncertainty_score":0.9994071},"labels":[],"label_agreement":null},{"id":"W2085013428","doi":"10.1517/14728214.13.2.363","title":"Emerging antidyslipidemic drugs","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Ezetimibe; Tolerability; Adverse effect; Intensive care medicine; Coronary heart disease; Niacin; Pharmacology; Statin; Internal medicine","score_opus":0.04300957262493703,"score_gpt":0.3725274129698519,"score_spread":0.3295178403449149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085013428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000792055,0.9839692,0.0000730006,0.0008322928,0.00475935,0.0019424385,0.00001757065,0.0004694248,0.007928778],"genre_scores_gemma":[0.000017396307,0.9884592,0.0003680525,0.0013355273,0.0075817793,0.00041112772,0.0005188676,0.00035661907,0.00095139723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936939,0.00047557385,0.0015778614,0.0014549814,0.0016922778,0.0011053985],"domain_scores_gemma":[0.9962808,0.00021670481,0.00060902914,0.0021525938,0.00014496711,0.00059589936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081371295,0.0011841344,0.0042156484,0.00084586727,0.00049535034,0.00003756418,0.0004601792,0.00070917443,0.0002711324],"category_scores_gemma":[0.00021599547,0.00095535285,0.0032059448,0.0009457857,0.00012270395,0.00013144688,0.00018516296,0.001505572,0.0006922972],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002105182,0.00014085647,0.0000015824018,0.0049148155,0.0005518671,0.000043507538,0.0012507688,0.000001446893,4.6638476e-7,0.0001656332,0.042917963,0.94999003],"study_design_scores_gemma":[0.00094457885,0.00016412558,0.0000025043378,0.030368272,0.00010223675,0.00044934914,0.00029983945,0.000025851694,0.000005348135,0.000006311101,0.96678007,0.0008514896],"about_ca_topic_score_codex":0.00029092177,"about_ca_topic_score_gemma":4.58541e-7,"teacher_disagreement_score":0.9491385,"about_ca_system_score_codex":0.00059358275,"about_ca_system_score_gemma":0.0009397188,"threshold_uncertainty_score":0.9992897},"labels":[],"label_agreement":null},{"id":"W2091075249","doi":"10.1517/14728214.12.3.367","title":"Pharmacologic therapeutics for cardiac reperfusion injury","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; University of Lethbridge","keywords":"Medicine; Mitochondrial permeability transition pore; Cardioprotection; Reperfusion injury; Pharmacology; Bradykinin; Potassium channel; Myocardial infarction; Receptor; Ischemia; Internal medicine; Programmed cell death; Biochemistry; Chemistry; Apoptosis","score_opus":0.08498793500887913,"score_gpt":0.44869112029704383,"score_spread":0.3637031852881647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091075249","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005984191,0.9826638,0.000057319936,0.00043290821,0.010163839,0.00275217,0.000058015336,0.0002775037,0.003534597],"genre_scores_gemma":[0.0000146575185,0.9894802,0.0004696423,0.0014005292,0.0055348324,0.00047007162,0.0008055361,0.00021051537,0.0016140001],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655795,0.00015645706,0.00096079963,0.0009787463,0.00067807134,0.00066800194],"domain_scores_gemma":[0.9979121,0.00042561273,0.00040400148,0.0008267298,0.00017838816,0.00025316348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087595545,0.0008109306,0.0024827886,0.00050481653,0.00029658852,0.00002892135,0.00022780149,0.00089906075,0.00013258254],"category_scores_gemma":[0.00006264323,0.00058008754,0.0024710328,0.00046094117,0.00008574139,0.00004925332,0.0001404949,0.0008382799,0.00010111655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020336975,0.0001677849,0.0000011112728,0.0028915165,0.0003443059,0.000005644486,0.0003721739,2.2226574e-7,0.0008386612,0.000054774046,0.042037968,0.95308244],"study_design_scores_gemma":[0.00072341296,0.0003781652,1.8829009e-7,0.009998541,0.00034798705,0.000023860994,0.00013765051,0.00001586748,0.002738766,0.0000032220637,0.9850101,0.0006222387],"about_ca_topic_score_codex":0.000008714834,"about_ca_topic_score_gemma":2.427937e-8,"teacher_disagreement_score":0.9524602,"about_ca_system_score_codex":0.00043621965,"about_ca_system_score_gemma":0.00036608303,"threshold_uncertainty_score":0.9996651},"labels":[],"label_agreement":null},{"id":"W2092130790","doi":"10.1517/14728214.2010.517746","title":"Emerging therapies for cystic fibrosis lung disease","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Cystic fibrosis; Mucociliary clearance; Medicine; Chloride channel; Airway; Lung; Cystic fibrosis transmembrane conductance regulator; Fibrosis; Respiratory system; Lung disease; Ion channel; Pathology; Internal medicine; Receptor; Cell biology; Anesthesia; Biology","score_opus":0.03499504691110344,"score_gpt":0.4096748499475913,"score_spread":0.37467980303648785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092130790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027049134,0.99010056,0.0012662759,0.0015044821,0.0030732858,0.003190983,0.00024154883,0.0003163553,0.0003037743],"genre_scores_gemma":[0.00001776971,0.98630995,0.005452945,0.0002563493,0.0028882832,0.0023526058,0.0012710795,0.00032615964,0.001124853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536395,0.00019436942,0.0010322308,0.0012370778,0.0011227077,0.0010496638],"domain_scores_gemma":[0.9958069,0.0014558117,0.00043446358,0.0013180949,0.00021877278,0.00076596724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052821124,0.0009727627,0.0022167931,0.00076321344,0.00044805725,0.000119578355,0.0005456067,0.000352077,0.00041772536],"category_scores_gemma":[0.0014096576,0.00075865287,0.0013635219,0.0005479359,0.00019878469,0.00018362404,0.00016941618,0.001017346,0.00012199584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031742465,0.00017764968,0.0000027440058,0.014688944,0.0002511217,0.000009213845,0.0005811214,0.0000026385885,0.000036581318,0.00040912413,0.019858748,0.9636647],"study_design_scores_gemma":[0.00086836546,0.00020133534,0.000006021119,0.033401765,0.00014509284,0.000012524128,0.00016218716,0.0005962377,0.0000097576885,0.00006685383,0.96382487,0.0007049803],"about_ca_topic_score_codex":0.00001920545,"about_ca_topic_score_gemma":7.545345e-7,"teacher_disagreement_score":0.9629597,"about_ca_system_score_codex":0.00034708704,"about_ca_system_score_gemma":0.00065446383,"threshold_uncertainty_score":0.99948645},"labels":[],"label_agreement":null},{"id":"W2122042922","doi":"10.1517/14728214.2012.681301","title":"Emerging drugs for major depressive disorder: an update","year":2012,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Major depressive disorder; Psychiatry; Pharmacology; Mood","score_opus":0.013876679629682066,"score_gpt":0.33894847378183945,"score_spread":0.32507179415215737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122042922","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010689769,0.030412648,0.0006436944,0.0041488037,0.9576156,0.0028997224,0.0005169112,0.0010027908,0.0016908532],"genre_scores_gemma":[0.004491134,0.011191552,0.0031867616,0.0006896248,0.958465,0.0019254507,0.015597818,0.00083871646,0.0036139393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99300957,0.0002458386,0.0011002753,0.0018686972,0.0022897087,0.0014859253],"domain_scores_gemma":[0.9951361,0.0008207802,0.0008345878,0.0019477818,0.00045387042,0.000806908],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000610057,0.0014042394,0.0015695968,0.00072345167,0.0007412743,0.00012253856,0.0007121207,0.0014545344,0.00051340525],"category_scores_gemma":[0.0006098194,0.0012312375,0.00073694094,0.00029296798,0.00012980403,0.0005951783,0.00029434377,0.0013050198,0.00025082863],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014665399,0.0010962478,0.00009996644,0.00029709292,0.00042952053,0.000010309708,0.0040201647,0.000015068575,0.00019673459,0.000105059604,0.913377,0.07888634],"study_design_scores_gemma":[0.009766604,0.0007221829,0.00005097139,0.0018620521,0.00018082208,0.0000052827986,0.00096397754,0.0002479601,0.0011668453,0.00007637429,0.98375887,0.0011980664],"about_ca_topic_score_codex":0.00030123157,"about_ca_topic_score_gemma":0.000007037772,"teacher_disagreement_score":0.07768827,"about_ca_system_score_codex":0.00051457837,"about_ca_system_score_gemma":0.00036824285,"threshold_uncertainty_score":0.9998708},"labels":[],"label_agreement":null},{"id":"W2127246176","doi":"10.1517/14728214.12.1.113","title":"Emerging drugs in neuropathic pain","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University","funders":"Canadian Institutes of Health Research; Pfizer","keywords":"Medicine; Neuropathic pain; Pharmacology; Chronic pain; Adverse effect; Clinical trial; Population; Intensive care medicine; Bioinformatics; Psychiatry; Internal medicine","score_opus":0.05585911933335879,"score_gpt":0.39008517709162505,"score_spread":0.33422605775826625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127246176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008497539,0.992014,0.00042812637,0.0004626495,0.0024390635,0.0012843326,0.000009857363,0.00025252436,0.0031009854],"genre_scores_gemma":[0.00009886637,0.99489254,0.00060231995,0.001562251,0.0011079395,0.00026854457,0.00036502158,0.00026534585,0.0008371461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99430484,0.0012665247,0.0013083857,0.00120903,0.000935371,0.00097585603],"domain_scores_gemma":[0.9973799,0.0007554136,0.00044844017,0.0009921109,0.00006360703,0.00036051768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041661584,0.0010254261,0.0023622406,0.0013473356,0.00018562545,0.00003833168,0.00033756057,0.0005403956,0.00023208909],"category_scores_gemma":[0.00044226146,0.00085298147,0.0008322143,0.0010102388,0.000051652547,0.000091159476,0.00012564631,0.0011854921,0.00036359022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003223731,0.0003714339,0.00001010097,0.002443404,0.00012285796,0.00018861717,0.0015009228,0.0000011562834,0.0000016871222,0.00039004307,0.0019164144,0.99302113],"study_design_scores_gemma":[0.0010387108,0.0002367482,0.0000054526527,0.034369864,0.00005132276,0.00003907936,0.0004179441,0.00022145417,0.000006714862,0.000031197622,0.9629489,0.0006325747],"about_ca_topic_score_codex":0.00012549489,"about_ca_topic_score_gemma":0.0000016916713,"teacher_disagreement_score":0.99238855,"about_ca_system_score_codex":0.0005606624,"about_ca_system_score_gemma":0.0002867171,"threshold_uncertainty_score":0.9993921},"labels":[],"label_agreement":null},{"id":"W2140016150","doi":"10.1517/14728214.2015.1050376","title":"Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Tardive dyskinesia; Neurochemical; Dopamine; Medicine; Dopamine receptor D2; Pharmacology; Antipsychotic; Monoamine neurotransmitter; Dyskinesia; Neuroscience; Dopamine receptor; Schizophrenia (object-oriented programming); Serotonin; Internal medicine; Receptor; Psychology; Psychiatry; Parkinson's disease","score_opus":0.2655091623101564,"score_gpt":0.5465815142672025,"score_spread":0.28107235195704605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140016150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006084462,0.97805935,0.000056286586,0.0044868067,0.0033885094,0.0071976,0.00029314795,0.00017031572,0.00026351926],"genre_scores_gemma":[0.0020766193,0.9857223,0.0022156213,0.0004344526,0.0039951797,0.0019711065,0.0031027216,0.00021203866,0.00026994466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901991,0.0017209926,0.003757405,0.0018030875,0.0014770223,0.0010424004],"domain_scores_gemma":[0.9934073,0.002572186,0.0012891546,0.00097445113,0.00039665194,0.0013602517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008474432,0.0011999587,0.005885915,0.0013445407,0.00041973256,0.0000954967,0.000396146,0.0007358713,0.00014254429],"category_scores_gemma":[0.002902134,0.00092552113,0.0014682253,0.0008688324,0.00025093506,0.00024132204,0.00021894912,0.0012497546,0.000050215913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008068103,0.0029402985,0.0000075102644,0.0013870422,0.0008578133,0.00003852655,0.0025234441,4.6903264e-7,0.000005946123,0.00063127663,0.021139111,0.96240044],"study_design_scores_gemma":[0.08215375,0.003453853,0.0000058788696,0.012972113,0.00035804353,0.000042499552,0.0008438444,0.0004695757,0.00002678902,0.0003728044,0.8984634,0.0008374069],"about_ca_topic_score_codex":0.00007868994,"about_ca_topic_score_gemma":0.0000029378639,"teacher_disagreement_score":0.96156305,"about_ca_system_score_codex":0.0005211837,"about_ca_system_score_gemma":0.0022869308,"threshold_uncertainty_score":0.99931955},"labels":[],"label_agreement":null},{"id":"W2144409780","doi":"10.1517/14728214.6.2.281","title":"Pharmacological treatment for prevention of restenosis","year":2001,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Pfizer","keywords":"Restenosis; Medicine; Intimal hyperplasia; Neointimal hyperplasia; Cardiology; Angioplasty; Coronary artery disease; Conventional PCI; Internal medicine; Percutaneous coronary intervention; Neointima; Interventional cardiology; Stent; Myocardial infarction; Smooth muscle","score_opus":0.08141778822303335,"score_gpt":0.4207583856965823,"score_spread":0.33934059747354894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144409780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964562,0.0053030467,0.0045889975,0.013486182,0.0024063715,0.001955747,0.000031724405,0.00017747495,0.0074884575],"genre_scores_gemma":[0.9891104,0.0063961255,0.0013848996,0.00031130496,0.00039524047,0.00025375598,0.00009922293,0.000016354834,0.0020326604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992682,0.000025759253,0.00025598574,0.00017897582,0.00012974594,0.00014133155],"domain_scores_gemma":[0.9995193,0.00012976174,0.000074061696,0.00013903208,0.000069204856,0.00006867605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006786648,0.00010467058,0.00019012601,0.0000905537,0.000060549326,0.0000040563123,0.000040533796,0.000046537898,0.0005224387],"category_scores_gemma":[0.000054562664,0.00008223212,0.00024577923,0.00009105032,0.000023510107,0.00003186,0.000012632995,0.000035799265,0.0000125111155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041239867,0.010749085,0.006578841,0.00009296414,0.000531439,0.000023414845,0.0028210955,0.00015883206,0.0119185895,0.0046941126,0.06792331,0.8903843],"study_design_scores_gemma":[0.00775588,0.009654074,0.0074780793,0.00061968464,0.00006371621,0.00002496621,0.0011290072,0.0017902373,0.021058386,0.0002733551,0.9499407,0.00021191449],"about_ca_topic_score_codex":0.00002618382,"about_ca_topic_score_gemma":9.66316e-7,"teacher_disagreement_score":0.8901724,"about_ca_system_score_codex":0.000087917455,"about_ca_system_score_gemma":0.000022388105,"threshold_uncertainty_score":0.57203376},"labels":[],"label_agreement":null},{"id":"W2147313898","doi":"10.1517/14728214.9.2.223","title":"Use of cytokines in infection","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Immune system; Immunology; Medicine; Adjuvant; Cytokine; Antimicrobial; Antibiotics; Vaccination; Infectious disease (medical specialty); Proinflammatory cytokine; Disease; Biology; Inflammation; Microbiology; Internal medicine","score_opus":0.1613996187446005,"score_gpt":0.4539644417797895,"score_spread":0.29256482303518905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147313898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045899502,0.9966783,0.000018728897,0.00017911672,0.00086959696,0.0009989254,0.000016737102,0.000072980714,0.0011197178],"genre_scores_gemma":[0.00010576045,0.9985138,0.0002052692,0.000071983864,0.00039397637,0.00018461474,0.00020415697,0.00009661336,0.00022378801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974212,0.00022280018,0.0008549162,0.00047331923,0.000665174,0.00036256466],"domain_scores_gemma":[0.9987319,0.00021007565,0.00024438126,0.00057473563,0.00010468102,0.00013424267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030490314,0.00037384251,0.0015187997,0.0012413755,0.00004054237,0.000019160896,0.0001207161,0.0003488761,0.00018590382],"category_scores_gemma":[0.00047793004,0.00031338018,0.00041888934,0.00088492205,0.0000709908,0.00012908517,0.00008117036,0.0006556093,0.00013622915],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025267764,0.0002179287,0.00011220124,0.0077750324,0.00006513101,0.000016188984,0.00043404958,0.000009116974,0.0000030673425,0.00015654758,0.001452126,0.98973334],"study_design_scores_gemma":[0.00043506335,0.00016415713,0.000048808328,0.06139858,0.000010981296,0.000009000814,0.000008972177,0.000020842042,0.000022981032,0.000005018587,0.9376588,0.00021680644],"about_ca_topic_score_codex":0.0024060819,"about_ca_topic_score_gemma":0.000017830345,"teacher_disagreement_score":0.98951656,"about_ca_system_score_codex":0.00061796576,"about_ca_system_score_gemma":0.0005774084,"threshold_uncertainty_score":0.9999318},"labels":[],"label_agreement":null},{"id":"W2335279309","doi":"10.1517/14728214.2016.1170117","title":"Emerging drugs for graft-versus-host disease","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Disease; Clinical trial; Graft-versus-host disease; Immunology; Intensive care medicine; Internal medicine","score_opus":0.054858529043226835,"score_gpt":0.39320863521173127,"score_spread":0.3383501061685044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335279309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000032119228,0.98235965,0.0013627842,0.0020919312,0.00721321,0.0030684927,0.00025295385,0.0003997538,0.0032480329],"genre_scores_gemma":[0.000031066178,0.99119765,0.0006544629,0.00039351513,0.0027640187,0.0013766238,0.0013798841,0.00035837694,0.0018444167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952368,0.00020036843,0.0013478416,0.0013141808,0.0009937254,0.00090706936],"domain_scores_gemma":[0.99625874,0.0011311837,0.0005576114,0.0011652044,0.00016905447,0.00071821094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053704844,0.0010546343,0.0021742422,0.00067584624,0.00030982099,0.000052414638,0.0004081454,0.00041455496,0.0005341654],"category_scores_gemma":[0.00022090644,0.00080086134,0.0014552366,0.00042138624,0.00010507151,0.00015705662,0.00006534871,0.00042101668,0.0006627415],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073722145,0.00022034766,0.000001886829,0.02201208,0.0005059118,0.000025123312,0.0023067335,5.1642036e-7,0.0000082054685,0.0019954788,0.01851567,0.9536708],"study_design_scores_gemma":[0.0032656726,0.00017358652,0.0000016541907,0.06673377,0.00028928387,0.000013007261,0.0003187948,0.00003386486,0.000025537622,0.000022111095,0.92830145,0.00082128047],"about_ca_topic_score_codex":0.000013825864,"about_ca_topic_score_gemma":3.1058042e-7,"teacher_disagreement_score":0.95284957,"about_ca_system_score_codex":0.00045221034,"about_ca_system_score_gemma":0.000588078,"threshold_uncertainty_score":0.99944425},"labels":[],"label_agreement":null},{"id":"W2548436673","doi":"10.1080/14728214.2016.1257607","title":"Emerging drugs and therapeutics for systemic sclerosis","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Medicine; Intensive care medicine; Disease; Context (archaeology); Scleroderma (fungus); Interstitial lung disease; Multiple sclerosis; Systemic disease; Bioinformatics; Immunology; Pathology; Lung; Internal medicine","score_opus":0.07706061920886499,"score_gpt":0.37317207486498655,"score_spread":0.29611145565612157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548436673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028955863,0.9927651,0.000106494204,0.0011045156,0.0028398095,0.00237406,0.000064789,0.00027886286,0.0004373866],"genre_scores_gemma":[0.0003862351,0.99454325,0.00009169629,0.0007458853,0.0021827861,0.0008895646,0.00015137703,0.00027618097,0.00073301664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996056,0.00021917344,0.0013201503,0.0010857399,0.00063295005,0.0006859578],"domain_scores_gemma":[0.9973848,0.00049910566,0.0007033878,0.00087339577,0.00016756493,0.0003717743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005230745,0.000902285,0.0024137504,0.0005306573,0.0003501865,0.0000762247,0.00028815857,0.00067542767,0.000068204456],"category_scores_gemma":[0.000073937365,0.00057861436,0.0010782459,0.0003278052,0.00011333331,0.000092957285,0.00008715589,0.00035369108,0.000111357294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005914678,0.00009746864,0.0000022886566,0.009081059,0.00073578354,0.0000017961294,0.0013698821,2.3408026e-7,0.000052255917,0.00025615466,0.008728474,0.97961545],"study_design_scores_gemma":[0.0012955294,0.00012173827,0.0000013766437,0.27676898,0.0002706276,0.0000729711,0.0008251119,0.000028961345,0.000014086911,0.000006713309,0.7200826,0.0005113078],"about_ca_topic_score_codex":0.000014534852,"about_ca_topic_score_gemma":4.3996234e-8,"teacher_disagreement_score":0.97910416,"about_ca_system_score_codex":0.00033017443,"about_ca_system_score_gemma":0.0002862819,"threshold_uncertainty_score":0.9996665},"labels":[],"label_agreement":null},{"id":"W3023787781","doi":"10.1080/14728214.2020.1763954","title":"Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Dyskinesia; Pharmacology; Intensive care medicine; Internal medicine; Disease; Parkinson's disease","score_opus":0.0638396933316561,"score_gpt":0.38957649571567515,"score_spread":0.32573680238401903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023787781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007897616,0.99215114,0.00014826271,0.0015644642,0.002076641,0.00334585,0.00020414892,0.00017642262,0.00025410842],"genre_scores_gemma":[0.00078706077,0.9934274,0.0005566764,0.00032779633,0.0015908988,0.0016748873,0.0012182358,0.00023381585,0.00018324459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645823,0.00018031518,0.0009780722,0.0011401378,0.0006447736,0.00059845735],"domain_scores_gemma":[0.99734646,0.0002666671,0.0006593558,0.0011687014,0.00012319462,0.00043560957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019277242,0.0010316552,0.0025222986,0.00032184483,0.0003438148,0.000040195053,0.0003776346,0.00022938322,0.00013701322],"category_scores_gemma":[0.00003929402,0.00063496444,0.0014691324,0.00046806273,0.00004951806,0.00010303313,0.00005318007,0.00021745851,0.000077404264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022135301,0.0011382323,0.0000010906472,0.0013607695,0.0013321496,0.000034867986,0.00198046,0.0000015559376,0.000008097363,0.0004943665,0.0011406662,0.9922864],"study_design_scores_gemma":[0.0028767064,0.0016799382,0.0000033167557,0.0044254833,0.0008167479,0.00002036382,0.0007017689,0.00033947022,0.00017072381,0.000023168013,0.9884504,0.0004919039],"about_ca_topic_score_codex":0.000086883956,"about_ca_topic_score_gemma":0.0000011242195,"teacher_disagreement_score":0.99179447,"about_ca_system_score_codex":0.00045794676,"about_ca_system_score_gemma":0.00040636872,"threshold_uncertainty_score":0.9996102},"labels":[],"label_agreement":null},{"id":"W4230999927","doi":"10.1517/eoed.8.2.297.21133","title":"Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Telithromycin; Ketolide; Streptococcus pneumoniae; Microbiology; Macrolide Antibiotics; Erythromycin; Efflux; Medicine; Antibiotics; Biology","score_opus":0.05614382737932102,"score_gpt":0.3787878638256813,"score_spread":0.3226440364463603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230999927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95836705,0.002476923,0.0012527665,0.0072966474,0.007510258,0.003053506,0.0000626048,0.0012470882,0.018733155],"genre_scores_gemma":[0.99056756,0.00086059404,0.00023939586,0.0052230875,0.0014676199,0.00080737507,0.00004880855,0.00018365406,0.0006019092],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720824,0.00024518272,0.00063799083,0.0007971756,0.0004246883,0.00068673823],"domain_scores_gemma":[0.9982229,0.00021673125,0.00020333577,0.0007895027,0.00015894754,0.00040858774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041325614,0.00051970955,0.00054572703,0.0006791216,0.0010713695,0.00007328388,0.000104339786,0.00020201615,0.00010853347],"category_scores_gemma":[0.00023171765,0.00044415894,0.0003975201,0.00043623973,0.00008469834,0.00020331123,0.000016226679,0.00027228796,0.00006552255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018250127,0.0123413745,0.010185745,0.00033407507,0.0013348601,0.00014135597,0.018520348,0.0036581592,0.72360706,0.04183837,0.014351023,0.1718626],"study_design_scores_gemma":[0.0031547772,0.004448195,0.00072471553,0.0003711756,0.000029709314,0.000029032302,0.0013370309,0.00020515142,0.034463,0.0001313213,0.9545935,0.00051243824],"about_ca_topic_score_codex":0.000059465365,"about_ca_topic_score_gemma":0.0000148492345,"teacher_disagreement_score":0.9402424,"about_ca_system_score_codex":0.0006847074,"about_ca_system_score_gemma":0.00028758368,"threshold_uncertainty_score":0.99980104},"labels":[],"label_agreement":null},{"id":"W4236574143","doi":"10.1517/14728214.12.3.461","title":"Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory Support and Mechanisms","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; London Health Sciences Centre; Western University","funders":"National Institutes of Health","keywords":"Medicine; ARDS; Intensive care medicine; Population; Hypoxemia; Diffuse alveolar damage; Lung; Acute respiratory distress; Internal medicine","score_opus":0.022052531044507266,"score_gpt":0.3533447243498627,"score_spread":0.3312921933053554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236574143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472387,0.008244327,0.0024019985,0.0011098287,0.0015762609,0.0011798511,0.00010901834,0.00015345874,0.0005013921],"genre_scores_gemma":[0.99201286,0.003510096,0.0016839353,0.0011210233,0.0004977134,0.0001776478,0.00012826487,0.000101443155,0.0007670239],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982609,0.000028986555,0.000506183,0.0004403815,0.00033349948,0.000430023],"domain_scores_gemma":[0.99902046,0.00007714595,0.0001882467,0.0004114174,0.00008612184,0.00021660762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030033753,0.0003186962,0.00055037224,0.0003073015,0.00017643464,0.000015255077,0.00009179397,0.00012870636,0.000065380176],"category_scores_gemma":[0.000010566095,0.00025637267,0.00020865325,0.00016670492,0.00008115804,0.00011907606,0.000029788005,0.000068179936,0.0000033466804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006085996,0.0015132613,0.0086097205,0.00033611586,0.0038762747,0.0002906365,0.033696093,0.0000026931707,0.3318789,0.0040763984,0.009340351,0.6002936],"study_design_scores_gemma":[0.0062634894,0.0066392953,0.005259731,0.0004932974,0.0001736569,0.000068656205,0.0040954323,0.0001692808,0.20414466,0.000097749784,0.7719605,0.00063424016],"about_ca_topic_score_codex":0.000015453601,"about_ca_topic_score_gemma":7.399984e-7,"teacher_disagreement_score":0.76262015,"about_ca_system_score_codex":0.00011485619,"about_ca_system_score_gemma":0.000058216436,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W4365811101","doi":"10.1080/14728214.2023.2203912","title":"Emerging drugs in the treatment of chronic cough","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Chronic cough; Intensive care medicine; Narrative review; Disease; Expert opinion; Bioinformatics; Internal medicine; Asthma","score_opus":0.10327062259724018,"score_gpt":0.44266865039782566,"score_spread":0.3393980278005855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365811101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090014706,0.99251795,0.000002775711,0.000893501,0.0013023214,0.0018917966,0.000016496075,0.00011177598,0.0031733431],"genre_scores_gemma":[0.00009831916,0.9954846,0.000008741928,0.00012566852,0.0014490731,0.00082600804,0.00020322048,0.00014631433,0.0016580728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954638,0.0006288066,0.0012237714,0.00077065383,0.0011936915,0.00071931136],"domain_scores_gemma":[0.99756294,0.0006384287,0.0003790731,0.0011946947,0.00007932747,0.0001455166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009130894,0.0006756969,0.001993052,0.0008254888,0.00019701489,0.000031567644,0.0005193235,0.00043219764,0.00024188301],"category_scores_gemma":[0.00006943562,0.00040685642,0.000915583,0.0015964273,0.00014079163,0.00006793355,0.0000633539,0.0008328902,0.00040059738],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005709494,0.0006769751,0.0000021264766,0.0038742947,0.0003636224,0.00006482338,0.0088069085,0.000014269988,0.0000023016028,0.00031585558,0.0054760533,0.98034567],"study_design_scores_gemma":[0.0012007714,0.0011349845,0.0000043111395,0.022875827,0.00006888899,0.000016152178,0.0018451201,0.00009564795,0.000017007058,0.000011014431,0.9724053,0.00032495486],"about_ca_topic_score_codex":0.00016589626,"about_ca_topic_score_gemma":0.0000040375635,"teacher_disagreement_score":0.9800207,"about_ca_system_score_codex":0.0008498076,"about_ca_system_score_gemma":0.0008051488,"threshold_uncertainty_score":0.99983835},"labels":[],"label_agreement":null},{"id":"W4379598629","doi":"10.1080/14728214.2023.2218643","title":"Emerging peptide therapeutics for the treatment of ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ovarian cancer; Cancer; Peptide; Oncology; Internal medicine; Cancer research; Biology; Biochemistry","score_opus":0.09083098333692492,"score_gpt":0.4018117388492976,"score_spread":0.3109807555123727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379598629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057637803,0.98992276,0.000088434426,0.00069328025,0.00734129,0.0015602467,0.00017429788,0.00013006278,0.00008387494],"genre_scores_gemma":[0.000008292844,0.989006,0.000025221816,0.00016987884,0.0003763915,0.001785575,0.0003136219,0.00016526446,0.008149742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751717,0.00043532377,0.0008937006,0.00050306733,0.000085012376,0.00056573504],"domain_scores_gemma":[0.9966234,0.001866598,0.00059136894,0.0008280808,0.000074979165,0.00001557666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034048766,0.00065073575,0.0015112257,0.00030951106,0.0005510303,0.00002234177,0.00056647934,0.00044707212,0.0002976974],"category_scores_gemma":[0.000028459619,0.0003924542,0.0011722153,0.0003510718,0.0001887743,0.000042708114,0.0000436777,0.0002715467,0.00015426031],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028197304,0.00020550015,2.97411e-7,0.0005421246,0.0032246488,3.7989668e-7,0.005157569,0.000006225404,0.00019314128,0.00037622513,0.0038556254,0.9861563],"study_design_scores_gemma":[0.0011294263,0.00050620333,0.0000019038016,0.0044132248,0.00018148535,0.00000561319,0.0007613799,0.0000065621552,0.0006781816,0.000010928908,0.9919055,0.00039955275],"about_ca_topic_score_codex":0.00038118783,"about_ca_topic_score_gemma":0.000004551371,"teacher_disagreement_score":0.9880499,"about_ca_system_score_codex":0.0002045566,"about_ca_system_score_gemma":0.00028790094,"threshold_uncertainty_score":0.9998527},"labels":[],"label_agreement":null},{"id":"W4390744213","doi":"10.1080/14728214.2024.2303116","title":"Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crohn's disease; Janus kinase; Clinical trial; Disease; Vedolizumab; Narrative review; Inflammatory bowel disease; Intensive care medicine; Bioinformatics; Pharmacology; Immunology; Internal medicine; Cytokine","score_opus":0.053323533352468054,"score_gpt":0.40743744765041623,"score_spread":0.3541139142979482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013223107,0.99521714,0.000077374716,0.0003370604,0.00075428456,0.0026842323,0.0007449665,0.000015413281,0.0000372655],"genre_scores_gemma":[0.00007570589,0.9968586,0.00009826461,0.00015470896,0.00068857457,0.0011451173,0.00059983484,0.00008577905,0.00029342936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739283,0.00020322278,0.0012133274,0.0006818123,0.00024651093,0.00026231853],"domain_scores_gemma":[0.99814457,0.00018667881,0.00070516014,0.0006953742,0.000099202116,0.0001690158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081117306,0.00057068997,0.0016067404,0.00012743137,0.00017025987,0.000020576208,0.00021740784,0.00015768223,0.000023317729],"category_scores_gemma":[0.0002511395,0.00035675638,0.0009994933,0.00011769168,0.00014680253,0.0000059776985,0.00014092054,0.00008080607,0.0000010265059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000465981,0.0004929078,2.317195e-7,0.049471676,0.0009796938,0.000005088926,0.0007449501,6.803673e-7,0.000102828584,0.00027039554,0.00841265,0.93905294],"study_design_scores_gemma":[0.0018580022,0.00034634722,0.000002022011,0.036217418,0.0008447823,0.0000031486777,0.00010096333,0.000037549733,0.000057241814,0.0000064910823,0.9601965,0.00032955836],"about_ca_topic_score_codex":0.00001095779,"about_ca_topic_score_gemma":4.6735894e-7,"teacher_disagreement_score":0.95178384,"about_ca_system_score_codex":0.000041088984,"about_ca_system_score_gemma":0.00030065468,"threshold_uncertainty_score":0.9998884},"labels":[],"label_agreement":null},{"id":"W4391402131","doi":"10.1080/14728214.2024.2312817","title":"How will tovorafenib change our treatment of pediatric low-grade glioma?","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Glioma; Oncology; Intensive care medicine; Cancer research","score_opus":0.034070190485886775,"score_gpt":0.3377245327762583,"score_spread":0.3036543422903715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391402131","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039058132,0.09747001,0.0000016379252,0.01362257,0.8824698,0.0015684086,0.00045208508,0.00030595655,0.0002037387],"genre_scores_gemma":[0.031923957,0.080239385,0.000120548895,0.00008031714,0.8827962,0.0012574933,0.0022205564,0.0002638895,0.0010976241],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995833,0.000086317945,0.0006275573,0.001172341,0.0016195441,0.0006612501],"domain_scores_gemma":[0.99779457,0.00025186135,0.00039199446,0.00097319245,0.0002280493,0.00036035982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001264179,0.0009843028,0.0014233625,0.0009399714,0.00011368327,0.00009932968,0.00022298038,0.00081883086,0.00004199164],"category_scores_gemma":[0.00012494538,0.000746803,0.00087680074,0.0007068557,0.000035749385,0.00014749571,0.00008622472,0.00040452235,0.00011980751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019214433,0.0025958337,0.00006432516,0.0004714022,0.0006454766,0.000359237,0.0031564964,0.0000011477316,0.000118207805,0.000056698893,0.98223656,0.010102475],"study_design_scores_gemma":[0.004375028,0.002396748,0.000028348222,0.0011621863,0.0002622141,0.0000099547815,0.00073597895,0.000029489354,0.0029994086,0.000016853564,0.9874194,0.00056436064],"about_ca_topic_score_codex":0.00038099114,"about_ca_topic_score_gemma":0.0000045788056,"teacher_disagreement_score":0.028018145,"about_ca_system_score_codex":0.0007865113,"about_ca_system_score_gemma":0.00027941508,"threshold_uncertainty_score":0.9994983},"labels":[],"label_agreement":null},{"id":"W4394581977","doi":"10.1080/14728214.2024.2340723","title":"Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Dalhousie University","funders":"","keywords":"Medicine; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Clinical trial; Intensive care medicine; Pulmonary fibrosis; Disease; Lung; Internal medicine; Fibrosis","score_opus":0.07169041454626408,"score_gpt":0.436137698945395,"score_spread":0.36444728439913093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394581977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91846645,0.052909583,0.00015895757,0.013009369,0.009634317,0.0021357334,0.0002953855,0.0006245477,0.0027656837],"genre_scores_gemma":[0.97866195,0.016035007,0.0001709014,0.00061110285,0.0031335196,0.0002198308,0.0005526941,0.00011904706,0.0004959522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940242,0.0009577364,0.002378889,0.001200917,0.0007952165,0.00064304285],"domain_scores_gemma":[0.99774605,0.00036922842,0.0003594449,0.00093263696,0.000097616125,0.0004950435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022761084,0.00062734075,0.0017229002,0.0007399529,0.00023500182,0.000054223958,0.0002454781,0.00031673475,0.0003891074],"category_scores_gemma":[0.00023475675,0.00050484575,0.0011061999,0.00055398344,0.00015489238,0.00030791364,0.000087546905,0.0004758084,0.000114105205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072660334,0.026083864,0.00040450948,0.0009067458,0.00089226884,0.00057757227,0.029863166,0.00017556033,0.022875689,0.0061117806,0.010815758,0.8286328],"study_design_scores_gemma":[0.023597572,0.07438082,0.00069060986,0.021796871,0.0003668934,0.0001264598,0.0077735316,0.042394213,0.006279545,0.00053325144,0.8199832,0.0020770323],"about_ca_topic_score_codex":0.0002712578,"about_ca_topic_score_gemma":0.0000021019098,"teacher_disagreement_score":0.8265557,"about_ca_system_score_codex":0.00037425794,"about_ca_system_score_gemma":0.00032092663,"threshold_uncertainty_score":0.9997403},"labels":[],"label_agreement":null},{"id":"W4394816071","doi":"10.1080/14728214.2024.2339906","title":"Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Head and neck; Incidence (geometry); Monoclonal antibody; Head and neck cancer; Immunotherapy; Antibody; Cancer; Immunology; Surgery","score_opus":0.030195221107428807,"score_gpt":0.3631607518519307,"score_spread":0.3329655307445019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394816071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8435725,0.13201396,0.00027185061,0.01516842,0.003069874,0.0007210556,0.000021088097,0.0002938511,0.0048673884],"genre_scores_gemma":[0.98547035,0.009713608,0.00062143896,0.001745236,0.0013880815,0.0001366739,0.000060109996,0.00007420361,0.00079028757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984382,0.00002607148,0.0002885435,0.00055085326,0.00027779443,0.0004185422],"domain_scores_gemma":[0.9993694,0.0001516651,0.00003623803,0.00023123251,0.000057021574,0.00015443705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016664043,0.00028165983,0.00039342523,0.00019464472,0.00025508527,0.000044086297,0.000071280425,0.00008082799,0.00007026222],"category_scores_gemma":[0.000021180942,0.00023049898,0.00016168291,0.00019262319,0.00005443513,0.000093738294,0.0000395187,0.00019141531,0.000018104087],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029604884,0.0010352429,0.012983555,0.0015063742,0.00031379296,0.000109290624,0.07978518,0.000031514668,0.06553742,0.0036567512,0.2400831,0.59199727],"study_design_scores_gemma":[0.0037253266,0.0015466032,0.0058033713,0.00046851914,0.000008451734,0.000018573204,0.0015776488,0.0050949524,0.010096284,0.000062519015,0.9712231,0.00037466423],"about_ca_topic_score_codex":0.0001305336,"about_ca_topic_score_gemma":0.0000014873342,"teacher_disagreement_score":0.73113996,"about_ca_system_score_codex":0.000073989664,"about_ca_system_score_gemma":0.00009681239,"threshold_uncertainty_score":0.93994755},"labels":[],"label_agreement":null},{"id":"W4395667067","doi":"10.1080/14728214.2024.2346590","title":"Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Androgen receptor; Medicine; 5 Alpha-Reductase Inhibitor; Androgen; Finasteride; Pharmacology; Receptor; Internal medicine; Endocrinology; Prostate cancer; Hormone; Cancer","score_opus":0.04625012959276738,"score_gpt":0.35280377971852367,"score_spread":0.3065536501257563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395667067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002434213,0.9932793,0.000013139325,0.0015577674,0.0022266202,0.0015024078,0.00038552567,0.000120613775,0.00067125604],"genre_scores_gemma":[0.00012775426,0.9936591,0.00066604745,0.00032262498,0.0020537665,0.00048590044,0.0020682388,0.00016461516,0.00045195228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972827,0.00008000201,0.00072953023,0.001014491,0.00039622845,0.0004970356],"domain_scores_gemma":[0.99888873,0.0001346204,0.00016634585,0.00031661268,0.000052706833,0.00044099675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027240138,0.00067731127,0.0013063692,0.0005261537,0.00026826904,0.00008790066,0.00010703411,0.00033456314,0.00016561661],"category_scores_gemma":[0.00008129351,0.0005677961,0.000427395,0.0003384506,0.00016671984,0.00009012887,0.0000716043,0.00038381078,0.00005549453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008818725,0.00012828203,0.0000072509283,0.010006842,0.0002980381,0.000018675892,0.0013887445,2.1835518e-7,0.00001580371,0.0005810371,0.12907587,0.85839105],"study_design_scores_gemma":[0.0010189844,0.000302422,0.0000010301549,0.012210684,0.0001942664,0.0003210547,0.0005328561,0.00004525928,0.000033827313,0.00006391436,0.9847119,0.00056384545],"about_ca_topic_score_codex":0.000011684538,"about_ca_topic_score_gemma":7.726056e-7,"teacher_disagreement_score":0.8578272,"about_ca_system_score_codex":0.000109687724,"about_ca_system_score_gemma":0.00031203585,"threshold_uncertainty_score":0.99967736},"labels":[],"label_agreement":null},{"id":"W4399261264","doi":"10.1080/14728214.2024.2363215","title":"Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Weston Brain Institute","keywords":"Apathy; Medicine; Psychosis; Psychiatry; Disease; Adverse effect; Dementia; Cognitive decline; Alzheimer's disease; Intensive care medicine; Cognition; Pharmacology; Internal medicine","score_opus":0.10897566365268613,"score_gpt":0.47564281046541634,"score_spread":0.3666671468127302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399261264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025938012,0.9930167,0.000045601584,0.0019228086,0.0010988455,0.0033197752,0.000120503784,0.000075415606,0.00037440596],"genre_scores_gemma":[0.00020962498,0.99335104,0.0002009601,0.00021062462,0.00057383726,0.0035682414,0.0008854673,0.00013095916,0.0008692176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971656,0.00015716121,0.0008867493,0.00074424257,0.0005792243,0.00046700248],"domain_scores_gemma":[0.99865603,0.00026683975,0.0002196483,0.000445768,0.0001928968,0.00021879519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002858001,0.00057713233,0.001444849,0.0009748146,0.00008378226,0.000040388353,0.00015955589,0.00013148096,0.00024706294],"category_scores_gemma":[0.0000910549,0.00037114235,0.0008329179,0.00062601105,0.00007227392,0.00007828317,0.00003527867,0.00013925465,0.000060225342],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004428215,0.000997261,0.0000490749,0.0047010067,0.001008077,0.000018441244,0.0030711698,3.1464882e-7,0.0000011359535,0.00017739092,0.008423957,0.9811093],"study_design_scores_gemma":[0.0016324592,0.0011898105,0.00005449076,0.022634303,0.00050410425,0.0000034604493,0.001136849,0.000055286848,0.0000128819665,0.00005770429,0.97238934,0.00032932617],"about_ca_topic_score_codex":0.00004401503,"about_ca_topic_score_gemma":0.0000039609135,"teacher_disagreement_score":0.98078,"about_ca_system_score_codex":0.00018308652,"about_ca_system_score_gemma":0.00043817493,"threshold_uncertainty_score":0.99987406},"labels":[],"label_agreement":null},{"id":"W4399385857","doi":"10.1080/14728214.2024.2363213","title":"Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Montréal","funders":"","keywords":"Medicine; Lower urinary tract symptoms; Hyperplasia; cGMP-specific phosphodiesterase type 5; Benign prostatic hyperplasia (BPH); Intensive care medicine; Primary care; Primary treatment; Modalities; 5 Alpha-Reductase Inhibitor; Urology; Prostate; Internal medicine; Gynecology; Erectile dysfunction; Finasteride; Cancer; Family medicine","score_opus":0.07313921420710602,"score_gpt":0.4351080879869832,"score_spread":0.3619688737798772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399385857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000566179,0.9873476,0.000042652584,0.0036894458,0.0020611626,0.0050659236,0.00029644466,0.0001237327,0.0013673515],"genre_scores_gemma":[0.000031702733,0.9885935,0.00028143244,0.00011094481,0.0013150894,0.003004078,0.0009136848,0.00024219668,0.005507359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996038,0.00020842852,0.0011173923,0.00096389104,0.0008692466,0.00080305064],"domain_scores_gemma":[0.99739224,0.0008823532,0.000296247,0.0010401345,0.00015071675,0.00023830726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005825481,0.0008576859,0.0021119595,0.0006456884,0.00031702785,0.000071449045,0.00036320978,0.00026129413,0.00024480582],"category_scores_gemma":[0.00006268974,0.0004868195,0.001401412,0.0008010644,0.00014955114,0.00007424203,0.000101231795,0.0005128652,0.00027974352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020528035,0.00049100857,4.8681017e-7,0.012346814,0.0013788347,0.000025358398,0.007074992,0.0000027248966,0.000001952446,0.00049818703,0.035193298,0.9427811],"study_design_scores_gemma":[0.0011517422,0.0019176785,2.9885814e-7,0.014292404,0.0005830879,0.00006214869,0.0016779071,0.00035560114,0.000028755157,0.000057616144,0.97946733,0.00040541295],"about_ca_topic_score_codex":0.00009398223,"about_ca_topic_score_gemma":0.0000014112272,"teacher_disagreement_score":0.94427407,"about_ca_system_score_codex":0.00039710425,"about_ca_system_score_gemma":0.00076441,"threshold_uncertainty_score":0.99975836},"labels":[],"label_agreement":null},{"id":"W4404445324","doi":"10.1080/14728214.2024.2426649","title":"ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; McGill University; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Glioma; Cancer research","score_opus":0.06663130938689137,"score_gpt":0.4072833999992634,"score_spread":0.340652090612372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404445324","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012271794,0.35325536,0.000003353759,0.021329695,0.620971,0.0025446704,0.00016386778,0.00014818464,0.00035667449],"genre_scores_gemma":[0.00078446814,0.6556579,0.0006632374,0.0016751024,0.3374521,0.0012612245,0.0009691423,0.00023102347,0.0013058038],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99510044,0.0001597399,0.0012803896,0.001194044,0.0017191109,0.00054628076],"domain_scores_gemma":[0.9967736,0.0009451407,0.00033695358,0.001288988,0.00031974333,0.00033559513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007546783,0.0007343796,0.0017054729,0.0008624163,0.000054108077,0.000038000675,0.00042467876,0.00042543697,0.0004382089],"category_scores_gemma":[0.002562427,0.00047310037,0.00038568038,0.0011795906,0.000057260237,0.00011276181,0.00027852866,0.000727883,0.00046868544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006192374,0.0012983164,0.000013563382,0.0075503187,0.00015576383,0.00038810034,0.0008076076,0.0000015990751,0.00024358116,0.000015318908,0.97325927,0.015647337],"study_design_scores_gemma":[0.0019585032,0.0008560426,0.00002182077,0.1932649,0.00006780771,0.000009470568,0.00007227323,0.000015082948,0.0010118387,0.0000034730717,0.802335,0.00038374678],"about_ca_topic_score_codex":0.0007292437,"about_ca_topic_score_gemma":0.000024166064,"teacher_disagreement_score":0.30240253,"about_ca_system_score_codex":0.00038630713,"about_ca_system_score_gemma":0.0005958123,"threshold_uncertainty_score":0.9997721},"labels":[],"label_agreement":null},{"id":"W4406242635","doi":"10.1080/14728214.2025.2452514","title":"Seltorexant for major depressive disorder","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Major depressive disorder; Tolerability; Orexin; Medicine; Preclinical research; Cognition; Psychiatry; Neuroscience; Pharmacology; Clinical psychology; Psychology; Internal medicine; Receptor; Adverse effect; Neuropeptide","score_opus":0.07306809664989065,"score_gpt":0.42136772834151154,"score_spread":0.34829963169162087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406242635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.804299e-7,0.9890568,0.0008069272,0.00045061365,0.003940133,0.0021070163,0.00017938894,0.00019250142,0.003265903],"genre_scores_gemma":[0.000010810343,0.991994,0.000078418845,0.00046623164,0.00084435643,0.0033310093,0.00012435793,0.00011588489,0.003034928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960656,0.0004156894,0.00064601883,0.0013596845,0.0007190549,0.00079393963],"domain_scores_gemma":[0.99625474,0.0023526007,0.00026898223,0.0008732035,0.00007652624,0.00017393086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002552231,0.0006475505,0.001287076,0.00062005006,0.0006064352,0.00013402554,0.0011013569,0.00033802007,0.00017743693],"category_scores_gemma":[0.0013895049,0.0005048893,0.0007633005,0.0007741326,0.000111499554,0.00012462657,0.0003171589,0.0005431494,0.00015940191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025586758,0.0001317927,3.0222284e-7,0.003704699,0.00003752013,0.000004031003,0.0002398641,0.0000027910967,0.000004581574,0.0027450307,0.021791875,0.9713119],"study_design_scores_gemma":[0.00059164513,0.000062875915,1.1832601e-7,0.00974432,0.000018885446,0.0000039092356,0.00005465813,0.00008249919,0.00038759015,0.00009048534,0.98843336,0.0005296724],"about_ca_topic_score_codex":0.00002883038,"about_ca_topic_score_gemma":6.752877e-7,"teacher_disagreement_score":0.9707823,"about_ca_system_score_codex":0.00014837079,"about_ca_system_score_gemma":0.00037123638,"threshold_uncertainty_score":0.99974024},"labels":[],"label_agreement":null},{"id":"W4411195516","doi":"10.1080/14728214.2025.2517582","title":"Motor fluctuations in Parkinson disease – a mini-review of emerging drugs","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre; Toronto Western Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Parkinson's disease; Disease; Physical medicine and rehabilitation; Neuroscience; Intensive care medicine; Internal medicine; Psychology","score_opus":0.03519880348203243,"score_gpt":0.37833576729104834,"score_spread":0.3431369638090159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411195516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001040901,0.9908852,0.000008413278,0.0031932322,0.0008856005,0.0023638383,0.000103585604,0.00008249583,0.0024672248],"genre_scores_gemma":[0.000056701356,0.99389964,0.00011727072,0.0031114772,0.00016569094,0.001049208,0.00072512,0.00006580026,0.0008091067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646336,0.00030924112,0.0012830436,0.0008894628,0.00060993835,0.00044494885],"domain_scores_gemma":[0.9979732,0.00038849626,0.00045760936,0.00083130656,0.0000838077,0.0002655713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024725997,0.0006752564,0.0024110544,0.00067752093,0.000095929456,0.000011788964,0.00028608862,0.00019581035,0.0004107685],"category_scores_gemma":[0.0004905442,0.0005152798,0.0010412821,0.0009828453,0.00007015372,0.00006143299,0.000127531,0.00043682804,0.000058087313],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073385396,0.001017519,0.000026476373,0.06778634,0.00017114586,0.0000343305,0.00024893187,6.5407494e-7,3.457585e-7,0.00023005318,0.010145507,0.9202653],"study_design_scores_gemma":[0.0007248894,0.0001440344,0.0000560649,0.19848648,0.00017352807,9.587769e-7,0.000046278383,0.000017713528,4.6322725e-7,0.00005351486,0.80001855,0.00027752973],"about_ca_topic_score_codex":0.000046571313,"about_ca_topic_score_gemma":5.8832916e-7,"teacher_disagreement_score":0.9199878,"about_ca_system_score_codex":0.00015818373,"about_ca_system_score_gemma":0.00045694128,"threshold_uncertainty_score":0.9997299},"labels":[],"label_agreement":null},{"id":"W4414443225","doi":"10.1080/14728214.2025.2565189","title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Clinical trial; Myelin oligodendrocyte glycoprotein; Multiple sclerosis; Immunotherapy; Clinical neurology; Targeted therapy; Disease; MEDLINE","score_opus":0.11938186467696922,"score_gpt":0.4944612600731487,"score_spread":0.3750793953961795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414443225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018944007,0.97995096,0.000024499017,0.0034845767,0.0055194707,0.009840284,0.00043346605,0.00019853054,0.00052927225],"genre_scores_gemma":[0.000022102795,0.98128736,0.00012711463,0.00038215658,0.008420593,0.004233332,0.0030973149,0.00012231985,0.0023076872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99427015,0.000993643,0.0015887482,0.0012038273,0.0011061123,0.00083751784],"domain_scores_gemma":[0.99521095,0.0023029156,0.0006258945,0.0012228434,0.00024072513,0.00039665273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013567415,0.000892199,0.0030774034,0.0003614301,0.0006424608,0.00007651209,0.0005993348,0.0005519855,0.000105094834],"category_scores_gemma":[0.003024483,0.00051835494,0.002451247,0.00062743196,0.00016445314,0.000057363395,0.0002860321,0.00095967634,0.00006665951],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008369821,0.0009302186,0.000012968901,0.003164274,0.0023391086,0.000008242899,0.00018382078,4.1301556e-7,2.841094e-7,0.000058514244,0.07365125,0.9112811],"study_design_scores_gemma":[0.029771468,0.00074523425,0.0000854817,0.024760101,0.00044501142,9.399048e-7,0.00015063399,0.00007507533,9.993136e-7,0.000004085925,0.9435549,0.00040606537],"about_ca_topic_score_codex":0.00003175721,"about_ca_topic_score_gemma":0.0000029740818,"teacher_disagreement_score":0.910875,"about_ca_system_score_codex":0.00037431548,"about_ca_system_score_gemma":0.0011631778,"threshold_uncertainty_score":0.99972683},"labels":[],"label_agreement":null}]}